Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Lymphoblastic Leukemia
- Lymphoid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Relapsed Acute Lymphoblastic Leukemia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This is an open label, single arm, single center, phase 2 pilot study of Vyxeos induction & consolidation in relapsed and refractory ALL.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03575325
- Collaborators
- Jazz Pharmaceuticals
- Investigators
- Principal Investigator: Bijal Shah, M.D. H. Lee Moffitt Cancer Center and Research Institute
Get Well Soon